Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Chief Strategy Officer | October 02, 2017 | October 04, 2017 |
| Neurogene Inc.NGNE · Entity 5160 | Director · Chief Executive Officer | September 22, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date October 02, 2017 · Filed October 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,875 |
Reported balance
After 2017-10-02 transaction · row 1
1 source rowRow 1 · 2017-10-02 · Sale · Disposed 283 · Balance 16,875 F1: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.
Neurogene Inc.
Report date September 22, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,345,063 |
Reported balance
After 2026-09-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-22 · Exercise / conversion · Acquired 756 · Balance 1,345,063 F1: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.32 · Expires 2026-09-22 | Direct | 0 |
Reported balance
After 2026-09-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-22 · Exercise / conversion · Disposed 756 · Balance 0 F2: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.
F2: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Oct 2, 2026 22:49 UTC | Neurogene Inc. NGNE · Entity 5160 | Exercise / conversionStock Option (Right to Buy) · Derivative | 756 | $0.00 Strike: $25.32 | $0.00 |
DisclosureSEC source: 0001606302-26-000007 · wk-form4_1790966949.xml · derivative · entry 2 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 756 shares Expires 2026-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 22, 2026 Filed Oct 2, 2026 22:49 UTC | Neurogene Inc. NGNE · Entity 5160 | Exercise / conversionCommon Stock | 756 | $25.32 | $19,141.92 |
DisclosureSEC source: 0001606302-26-000007 · wk-form4_1790966949.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,345,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 21:38 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 3,352 | $22.07 | $73,995.06 |
DisclosureSEC source: 0001606302-26-000005 · wk-form4_1774905414.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,344,307 F1 · date: On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:48 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 155,100 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001606302-26-000002 · wk-form4_1771976903.xml · derivative · entry 2 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,100 Underlying: Common Stock · 155,100 shares Expires 2036-02-20 F3 · derivative.exercise_date: This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:48 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 25,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001606302-26-000002 · wk-form4_1771976903.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,347,659 F1 · shares: Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 · balance_after: Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:27 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantEmployee Stock Option (Right to buy) · Derivative | 143,500 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001404644-25-000020 · wk-form4_1743211653.xml · derivative · entry 2 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,500 Underlying: Common Stock · 143,500 shares Expires not disclosed F2 · derivative.expiration_date: This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:27 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 23,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001404644-25-000020 · wk-form4_1743211653.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,274,259 F1 · shares: Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 02:29 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 47,500 | $20.40 | $969,000.00 |
DisclosureSEC source: 0001404644-24-000112 · wk-form4_1732588138.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,297,859 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:54 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantEmployee Stock Option (Right to buy) · Derivative | 93,282 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0001404644-24-000010 · wk-form4_1710464082.xml · derivative · entry 1 McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,282 Underlying: Common Stock · 93,282 shares Expires 2034-03-13 F1 · derivative.exercise_date: The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 283 | $58.89 | $16,666.78 |
DisclosureSEC source: 0001144204-17-051412 · v476459_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 20:59 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 130 | $123.12 | $16,005.29 |
DisclosureSEC source: 0001144204-17-040071 · v472266_form4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,158 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 257 | $121.78 | $31,297.46 |
DisclosureSEC source: 0001144204-17-035810 · v470321_form4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,288 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 114 | $113.12 | $12,895.69 |
DisclosureSEC source: 0001144204-17-024325 · v466055_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,545 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 257 | $115.00 | $29,554.31 |
DisclosureSEC source: 0001144204-17-019297 · v463649_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 8,300 | $0.00 Strike: $107.18 | $0.00 |
DisclosureSEC source: 0001144204-17-006035 · v458369_4.xml · derivative · entry 2 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2027-02-01 F2 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on January 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006035 · v458369_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,916 F1 · shares: 25% of the shares of restricted stock will vest on January 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 816 | $103.92 | $84,797.99 |
DisclosureSEC source: 0001144204-17-000938 · v456333_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 129 | $123.82 | $15,972.33 |
DisclosureSEC source: 0001144204-16-131218 · v451999_4.xml · nonDerivative · entry 1 McMinn Rachel · CIK 0001606302 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,732 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.